Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome
This article was originally published in The Pink Sheet Daily
Executive Summary
Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.